SAB Biotherapeutics Inc. (SABS)
NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SABS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $253.15M
- EPS (TTM)
- -$1.35
- Dividend yield
- None
- 52-week range
- 2.44 – 5.15
- Day range
- 2.64 – 2.88
- Volume / Avg
- 874.57K / 633.60K
- Beta
- —
- Shares outstanding
- 90.09M
52-week range
SABS stock today
Shares of SAB Biotherapeutics (SABS) finished lower on Nov 20 at $2.81, a drop of 3.44% or $0.10 per share, versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $5.15, set on Mar 12, 2026 and 15.2% above the 52-week low of $2.44, near the bottom of the past year's range. SABS is down 24.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.9%.
SAB Biotherapeutics has posted a net loss over the last twelve months (EPS of -$1.35), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About SAB Biotherapeutics
Company profileSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Samuel J. Reich
- Headquarters
- Miami Beach, FL
- Employees
- 86
- IPO year
- 2021
- Website
- sab.bio
Financial highlights
Full financialsIn fiscal 2025, SAB Biotherapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Net income was $13.3 million. Diluted earnings per share came in at -$0.79.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.32M | $2.24M | $23.90M | $60.88M |
| Growth | -100.00% | -40.94% | -90.63% | -60.73% | +10.21% |
| Net income | $13.27M | $-34.11M | $-42.19M | $-18.74M | $-17.14M |
| EPS (diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-0.63 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$11.64+314.23%
- Strong buy 1
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.24 vs $-0.27
- Surprise
- +11.11%
SABS news
All SABS news- SAB BIO Reports Q3 2026 Financial Results and Provides Business HighlightsGlobeNewswire
- SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ETGlobeNewswire
- SAB BIO to Participate in Chardan 10th Annual Healthcare ConferenceGlobeNewswire
- SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 DiabetesGlobeNewswire
SAB Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs SABS |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs SABS |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs SABS |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs SABS |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs SABS |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs SABS |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs SABS |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs SABS |
Indexes, lists and sector
SAB Biotherapeutics stock FAQ
What is SAB Biotherapeutics's stock price today?
SABS last traded at $2.81 as of Nov 20, 4:00 PM EST, down 3.44% on the day. Prices are delayed at least 15 minutes.
Does SAB Biotherapeutics pay a dividend?
No. SAB Biotherapeutics does not currently pay a regular cash dividend.
Who is SAB Biotherapeutics's CEO?
Mr. Samuel J. Reich is the chief executive officer of SAB Biotherapeutics Inc., which has about 86 employees.
Has SABS ever split its stock?
Yes. The most recent SABS stock split was a 1-for-10 split on Jan 5, 2024.
What is the SABS 52-week high?
The 52-week high for SABS is $5.15 and the 52-week low is $2.44. The stock is currently 45.4% below its high.